The deal size was increased to 3M shares of common stock from 2.5M shares of common stock and priced at the high-end of the $45.00-$46.00 range. Piper Sandler, Guggenheim, Cantor Fitzgerald and Oppenheimer acted as joint book running managers for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock
- Soleno Therapeutics announces publication of data comparing DCCR treatment
- Soleno Therapeutics receives BTD from U.S. FDA for diazoxide choline
- Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)